Anti‐NGF antibodies, TRKA inhibitors, and NGF‐targeted siRNA delivered via nanoparticles have shown promise in reducing cancer growth and metastasis in animal models, and these approaches are advancing to clinical trials. This evidence concerns the gene NGF and cancer.